Cyclin-dependent Kinase 5 and Neurodegenerative Diseases.
Cyclin-dependent kinase 5
Mitochondrial dysfunction
Neurodegenerative diseases
Neuroinflammation
Oxidative stress
Journal
Molecular neurobiology
ISSN: 1559-1182
Titre abrégé: Mol Neurobiol
Pays: United States
ID NLM: 8900963
Informations de publication
Date de publication:
20 Feb 2024
20 Feb 2024
Historique:
received:
20
08
2023
accepted:
07
02
2024
medline:
21
2
2024
pubmed:
21
2
2024
entrez:
21
2
2024
Statut:
aheadofprint
Résumé
Neurodegenerative diseases are a group of diseases characterized by the progressive loss of neurons, including Alzheimer's disease, Parkinson's disease, and Amyotrophic lateral sclerosis. These diseases have a high incidence and mortality rate globally, placing a heavy burden on patients and their families. The pathogenesis of neurodegenerative diseases is complex, and there are no effective treatments at present. Cyclin-dependent kinase 5 is a proline-directed serine/threonine protein kinase that is closely related to the development and function of the nervous system. Under physiological conditions, it is involved in regulating the process of neuronal proliferation, differentiation, migration, and synaptic plasticity. Moreover, there is increasing evidence that cyclin-dependent kinase 5 also plays an important role in the pathogenesis of neurodegenerative diseases. In this review, we address the biological characteristics of cyclin-dependent kinase 5 and its role in neurodegenerative diseases. In particular, this review highlights the underlying mechanistic linkages between cyclin-dependent kinase 5 and mitochondrial dysfunction, oxidative stress and neuroinflammation in the context of neurodegeneration. Finally, we also summarize the currently available cyclin-dependent kinase 5 inhibitors and their prospects for the treatment of neurodegenerative diseases. Taken together, a better understanding of the molecular mechanisms of cyclin-dependent kinase 5 involved in neurodegenerative diseases can lead to the development of new strategies for the prevention and treatment of these devastating diseases.
Identifiants
pubmed: 38378992
doi: 10.1007/s12035-024-04047-1
pii: 10.1007/s12035-024-04047-1
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Mallucci GR, Klenerman D, Rubinsztein DC (2020) Developing therapies for neurodegenerative disorders: insights from protein aggregation and cellular stress responses. Ann Rev Cell Dev Biol 36:165–189
doi: 10.1146/annurev-cellbio-040320-120625
Wilson DM, Cookson MR, van den Bosch L, Zetterberg H, Holtzman DM, Dewachter I (2023) Hallmarks of neurodegenerative diseases. Cell 186:693–714
pubmed: 36803602
doi: 10.1016/j.cell.2022.12.032
Hisanaga S, Endo R (2010) Regulation and role of cyclin-dependent kinase activity in neuronal survival and death. J Neurochem 115:1309–1321
pubmed: 21044075
doi: 10.1111/j.1471-4159.2010.07050.x
Paoletti P, Vila I, Rife M, Lizcano JM, Alberch J, Gines S (2008) Dopaminergic and glutamatergic signaling crosstalk in Huntington’s disease neurodegeneration: the role of p25/cyclin-dependent kinase 5. J Neurosci 28:10090–10101
pubmed: 18829967
pmcid: 6671267
doi: 10.1523/JNEUROSCI.3237-08.2008
Su SC, Tsai LH (2011) Cyclin-dependent kinases in brain development and disease. Annu Rev Cell Dev Biol 27:465–491
pubmed: 21740229
doi: 10.1146/annurev-cellbio-092910-154023
Wilkaniec A, Gassowska-Dobrowolska M, Strawski M, Adamczyk A, Czapski GA (2018) Inhibition of cyclin-dependent kinase 5 affects early neuroinflammatory signalling in murine model of amyloid beta toxicity. J Neuroinflammation 15:1
pubmed: 29301548
pmcid: 5753486
doi: 10.1186/s12974-017-1027-y
Lew J, Beaudette K, Litwin CME, Wang JH (1992) Purification and Characterization of a Novel Proline-Directed Protein-Kinase from Bovine Brain. J Biol Chem 267:13383–13390
pubmed: 1618840
doi: 10.1016/S0021-9258(18)42222-3
Lew J, Winkfein RJ, Paudel HK, Wang JH (1992) Brain Proline-directed protein-kinase is a neurofilament kinase which displays high sequence homology to P34(Cdc2). J Biol Chem 267:25922–25926
pubmed: 1464604
doi: 10.1016/S0021-9258(18)35696-5
Tsai LH, Delalle I, Caviness VS Jr, Chae T, Harlow E (1994) p35 is a neural-specific regulatory subunit of cyclin-dependent kinase 5. Nature 371:419–423
pubmed: 8090221
doi: 10.1038/371419a0
Angelo M, Plattner F, Giese KP (2006) Cyclin-dependent kinase 5 in synaptic plasticity, learning and memory. J Neurochem 99:353–370
pubmed: 17029592
doi: 10.1111/j.1471-4159.2006.04040.x
Demetrick DJ, Zhang H, Beach DH (1994) Chromosomal Mapping of Human Cdk2, Cdk4, and Cdk5 Cell-Cycle Kinase Genes. Cytogenet Cell Genet 66:72–74
pubmed: 8275715
doi: 10.1159/000133669
Kobayashi S, Ishiguro K, Omori A, Takamatsu M, Arioka M, Imahori K, Uchida T (1993) A Cdc2-related kinase Pssalre/Cdk5 Is homologous with the 30 Kda subunit of tau-protein kinase-ii, a proline-directed protein-kinase associated with microtubule. FEBS Lett 335:171–175
pubmed: 8253190
doi: 10.1016/0014-5793(93)80723-8
Shelton SB, Johnson GV (2004) Cyclin-dependent kinase-5 in neurodegeneration. J Neurochem 88:1313–1326
pubmed: 15009631
doi: 10.1111/j.1471-4159.2003.02328.x
Batra S, Jahan S, Ashraf A, Alharby B, Jawaid T, Islam A, Hassan I (2023) A review on cyclin-dependent kinase 5: An emerging drug target for neurodegenerative diseases. Int J Biol Macromol 230:123259
pubmed: 36641018
doi: 10.1016/j.ijbiomac.2023.123259
Sharma P, Steinbach PJ, Sharma M, Amin ND, Barchi JJ Jr, Pant HC (1999) Identification of substrate binding site of cyclin-dependent kinase 5. J Biol Chem 274:9600–9606
pubmed: 10092646
doi: 10.1074/jbc.274.14.9600
Dhariwala FA, Rajadhyaksha MS (2008) An unusual member of the Cdk family: Cdk5. Cell Mol Neurobiol 28:351–369
pubmed: 18183483
doi: 10.1007/s10571-007-9242-1
Pao PC, Tsai LH (2021) Three decades of Cdk5. J Biomed Sci 28:79
pubmed: 34814918
pmcid: 8609871
doi: 10.1186/s12929-021-00774-y
Lew J, Huang QQ, Qi Z, Winkfein RJ, Aebersold R, Hunt T, Wang JH (1994) A brain-specific activator of cyclin-dependent kinase 5. Nature 371:423–426
pubmed: 8090222
doi: 10.1038/371423a0
Wu DC, Yu YP, Lee NT, Yu AC, Wang JH, Han YF (2000) The expression of Cdk5, p35, p39, and Cdk5 kinase activity in developing, adult, and aged rat brains. Neurochem Res 25:923–929
pubmed: 10959488
doi: 10.1023/A:1007544106645
Ko J, Humbert S, Bronson RT, Takahashi S, Kulkarni AB, Li E, Tsai LH (2001) p35 and p39 are essential for cyclin-dependent kinase 5 function during neurodevelopment. J Neurosci 21:6758–6771
pubmed: 11517264
pmcid: 6763073
doi: 10.1523/JNEUROSCI.21-17-06758.2001
Zheng M, Leung CL, Liem RK (1998) Region-specific expression of cyclin-dependent kinase 5 (cdk5) and its activators, p35 and p39, in the developing and adult rat central nervous system. J Neurobiol 35:141–159
pubmed: 9581970
doi: 10.1002/(SICI)1097-4695(199805)35:2<141::AID-NEU2>3.0.CO;2-4
Zhang X, Zhong T, Dang Y, Li Z, Li P, Chen G (2015) Aberrant expression of CDK5 infers poor outcomes for nasopharyngeal carcinoma patients. Int J Clin Exp Pathol 8:8066–8074
pubmed: 26339373
pmcid: 4555701
Ehrlich SM, Liebl J, Ardelt MA, Lehr T, De Toni EN, Mayr D, Brandl L, Kirchner T et al (2015) Targeting cyclin dependent kinase 5 in hepatocellular carcinoma–A novel therapeutic approach. J Hepatol 63:102–113
pubmed: 25660209
doi: 10.1016/j.jhep.2015.01.031
Rosales JL, Lee KY (2006) Extraneuronal roles of cyclin-dependent kinase 5. BioEssays 28:1023–1034
pubmed: 16998837
doi: 10.1002/bies.20473
Hellmich MR, Pant HC, Wada E, Battey JF (1992) Neuronal Cdc2-Like Kinase - a Cdc2-related protein-kinase with predominantly neuronal expression. P Natl Acad Sci USA 89:10867–10871
doi: 10.1073/pnas.89.22.10867
Patrick GN, Zhou P, Kwon YT, Howley PM, Tsai LH (1998) p35, the neuronal-specific activator of cyclin-dependent kinase 5 (Cdk5) is degraded by the ubiquitin-proteasome pathway. J Biol Chem 273:24057–24064
pubmed: 9727024
doi: 10.1074/jbc.273.37.24057
Patrick GN, Zukerberg L, Nikolic M, de la Monte S, Dikkes P, Tsai LH (1999) Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature 402:615–622
pubmed: 10604467
doi: 10.1038/45159
Kusakawa G, Saito T, Onuki R, Ishiguro K, Kishimoto T, Hisanaga S (2000) Calpain-dependent proteolytic cleavage of the p35 cyclin-dependent kinase 5 activator to p25. J Biol Chem 275:17166–17172
pubmed: 10748088
doi: 10.1074/jbc.M907757199
Lee MS, Kwon YT, Li M, Peng J, Friedlander RM, Tsai LH (2000) Neurotoxicity induces cleavage of p35 to p25 by calpain. Nature 405:360–364
pubmed: 10830966
doi: 10.1038/35012636
Metwally E, Zhao G, Zhang YQ (2021) The calcium-dependent protease calpain in neuronal remodeling and neurodegeneration. Trends Neurosci 44:741–752
pubmed: 34417060
doi: 10.1016/j.tins.2021.07.003
Baudry M, Bi X (2016) Calpain-1 and Calpain-2: the yin and yang of synaptic plasticity and neurodegeneration. Trends Neurosci 39:235–245
pubmed: 26874794
pmcid: 4818674
doi: 10.1016/j.tins.2016.01.007
Vosler PS, Brennan CS, Chen J (2008) Calpain-mediated signaling mechanisms in neuronal injury and neurodegeneration. Mol Neurobiol 38:78–100
pubmed: 18686046
pmcid: 2726710
doi: 10.1007/s12035-008-8036-x
Asada A, Yamamoto N, Gohda M, Saito T, Hayashi N, Hisanaga S (2008) Myristoylation of p39 and p35 is a determinant of cytoplasmic or nuclear localization of active cyclin-dependent kinase 5 complexes. J Neurochem 106:1325–1336
pubmed: 18507738
doi: 10.1111/j.1471-4159.2008.05500.x
Pozo K, Bibb JA (2016) The emerging role of Cdk5 in cancer. Trends Cancer 2:606–618
pubmed: 27917404
pmcid: 5132345
doi: 10.1016/j.trecan.2016.09.001
Tarricone C, Dhavan R, Peng J, Areces LB, Tsai LH, Musacchio A (2001) Structure and regulation of the CDK5-p25(nck5a) complex. Mol Cell 8:657–669
pubmed: 11583627
doi: 10.1016/S1097-2765(01)00343-4
Nikolic M, Dudek H, Kwon YT, Ramos YF, Tsai LH (1996) The cdk5/p35 kinase is essential for neurite outgrowth during neuronal differentiation. Genes Dev 10:816–825
pubmed: 8846918
doi: 10.1101/gad.10.7.816
Tsai LH, Takahashi T, Caviness VS Jr, Harlow E (1993) Activity and expression pattern of cyclin-dependent kinase 5 in the embryonic mouse nervous system. Development 119:1029–1040
pubmed: 8306873
doi: 10.1242/dev.119.4.1029
Baumann K, Mandelkow EM, Biernat J, Piwnica-Worms H, Mandelkow E (1993) Abnormal Alzheimer-like phosphorylation of tau-protein by cyclin-dependent kinases cdk2 and cdk5. FEBS Lett 336:417–424
pubmed: 8282104
doi: 10.1016/0014-5793(93)80849-P
Kawauchi T, Chihama K, Nishimura YV, Nabeshima Y, Hoshino M (2005) MAP1B phosphorylation is differentially regulated by Cdk5/p35, Cdk5/p25, and JNK. Biochem Bioph Res Co 331:50–55
doi: 10.1016/j.bbrc.2005.03.132
Lalioti V, Pulido D, Sandoval IV (2010) Cdk5, the multifunctional surveyor. Cell Cycle 9:284–311
pubmed: 20061803
doi: 10.4161/cc.9.2.10466
Li BS, Zhang L, Gu JG, Amin ND, Pant HC (2000) Integrin alpha(1)beta(1)-mediated activation of cyclin-dependent kinase 5 activity is involved in neurite outgrowth and human neurofilament protein H Lys-Ser-Pro tail domain phosphorylation. J Neurosci 20:6055–6062
pubmed: 10934255
pmcid: 6772578
doi: 10.1523/JNEUROSCI.20-16-06055.2000
Ohshima T, Ward JM, Huh CG, Longenecker G, Veeranna, Pant HC, Brady RO, Martin LJ et al (1996) Targeted disruption of the cyclin-dependent kinase 5 gene results in abnormal corticogenesis, neuronal pathology and perinatal death. Proc Natl Acad Sci U S A 93:11173–11178
pubmed: 8855328
pmcid: 38303
doi: 10.1073/pnas.93.20.11173
Tanaka T, Veeranna, Ohshima T, Rajan P, Amin ND, Cho A, Sreenath T, Pant HC et al (2001) Neuronal cyclin-dependent kinase 5 activity is critical for survival. J Neurosci 21:550–558
pubmed: 11160434
pmcid: 6763824
doi: 10.1523/JNEUROSCI.21-02-00550.2001
Chae T, Kwon YT, Bronson R, Dikkes P, Li E, Tsai LH (1997) Mice lacking p35, a neuronal specific activator of Cdk5, display cortical lamination defects, seizures, and adult lethality. Neuron 18:29–42
pubmed: 9010203
doi: 10.1016/S0896-6273(01)80044-1
Jahan I, Adachi R, Egawa R, Nomura H, Kuba H (2023) CDK5/p35-dependent microtubule reorganization contributes to homeostatic shortening of the axon initial segment. J Neurosci 43:359–372
pubmed: 36639893
pmcid: 9864565
doi: 10.1523/JNEUROSCI.0917-22.2022
Amin ND, Zheng YL, Kesavapany S, Kanungo J, Guszczynski T, Sihag RK, Rudrabhatla P, Albers W, Grant P, Pant HC (2008) Cyclin-dependent kinase 5 phosphorylation of human septin SEPT5 (hCDCrel-1) modulates exocytosis. J Neurosci 28:3631–3643
pubmed: 18385322
pmcid: 6671095
doi: 10.1523/JNEUROSCI.0453-08.2008
Fletcher AI, Shuang R, Giovannucci DR, Zhang L, Bittner MA, Stuenkel EL (1999) Regulation of exocytosis by cyclin-dependent kinase 5 via phosphorylation of Munc18. J Biol Chem 274:4027–4035
pubmed: 9933594
doi: 10.1074/jbc.274.7.4027
Kim SH, Ryan TA (2010) CDK5 serves as a major control point in neurotransmitter release. Neuron 67:797–809
pubmed: 20826311
pmcid: 2939042
doi: 10.1016/j.neuron.2010.08.003
Lee SY, Wenk MR, Kim Y, Naim AC, De Camilli P (2004) Regulation of synaptojanin 1 by cyclin-dependent kinase 5 at synapses. P Natl Acad Sci USA 101:546–551
doi: 10.1073/pnas.0307813100
Tan TC, Valova VA, Malladi CS, Graham ME, Berven LA, Jupp OJ, Hansra G, McClure SJ et al (2003) Cdk5 is essential for synaptic vesicle endocytosis. Nat Cell Biol 5:701–710
pubmed: 12855954
doi: 10.1038/ncb1020
Tomizawa K, Ohta J, Matsushita M, Moriwaki A, Li ST, Takei K, Matsui H (2002) Cdk5/p35 regulates neurotransmitter release through phosphorylation and downregulation of P/Q-type voltage-dependent calcium channel activity. J Neurosci 22:2590–2597
pubmed: 11923424
pmcid: 6758295
doi: 10.1523/JNEUROSCI.22-07-02590.2002
Cheung ZH, Ip NY (2012) Cdk5: a multifaceted kinase in neurodegenerative diseases. Trends Cell Biol 22:169–175
pubmed: 22189166
doi: 10.1016/j.tcb.2011.11.003
Smith DS, Tsai LH (2002) Cdk5 behind the wheel: a role in trafficking and transport? Trends Cell Biol 12:28–36
pubmed: 11854007
doi: 10.1016/S0962-8924(01)02181-X
Shea TB, Yabe JT, Ortiz D, Pimenta A, Loomis P, Goldman RD, Amin N, Pant HC (2004) Cdk5 regulates axonal transport and phosphorylation of neurofilaments in cultured neurons. J Cell Sci 117:933–941
pubmed: 14762105
doi: 10.1242/jcs.00785
Zhang Q, Ahuja HS, Zakeri ZF, Wolgemuth DJ (1997) Cyclin-dependent kinase 5 is associated with apoptotic cell death during development and tissue remodeling. Dev Biol 183:222–233
pubmed: 9126296
doi: 10.1006/dbio.1996.8494
Weishaupt JH, Kussmaul L, Grotsch P, Heckel A, Rohde G, Romig H, Bahr M, Gillardon F (2003) Inhibition of CDK5 is protective in necrotic and apoptotic paradigms of neuronal cell death and prevents mitochondrial dysfunction. Mol Cell Neurosci 24:489–502
pubmed: 14572469
doi: 10.1016/S1044-7431(03)00221-5
Camins A, Verdaguer E, Folch J, Canudas AM, Pallas M (2006) The role of CDK5/P25 formation/inhibition in neurodegeneration. Drug News Perspect 19:453–460
pubmed: 17160145
doi: 10.1358/dnp.2006.19.8.1043961
Jahani-Asl A, Huang E, Irrcher I, Rashidian J, Ishihara N, Lagace DC, Slack RS, Park DS (2015) CDK5 phosphorylates DRP1 and drives mitochondrial defects in NMDA-induced neuronal death. Hum Mol Genet 24:4573–4583
pubmed: 26002103
pmcid: 4512627
doi: 10.1093/hmg/ddv188
Rong R, Xia X, Peng H, Li H, You M, Liang Z, Yao F, Yao X et al (2020) Cdk5-mediated Drp1 phosphorylation drives mitochondrial defects and neuronal apoptosis in radiation-induced optic neuropathy. Cell Death Dis 11:720
pubmed: 32883957
pmcid: 7473761
doi: 10.1038/s41419-020-02922-y
Gong X, Tang X, Wiedmann M, Wang X, Peng J, Zheng D, Blair LA, Marshall J et al (2003) Cdk5-mediated inhibition of the protective effects of transcription factor MEF2 in neurotoxicity-induced apoptosis. Neuron 38:33–46
pubmed: 12691662
doi: 10.1016/S0896-6273(03)00191-0
Li BS, Zhang L, Takahashi S, Ma W, Jaffe H, Kulkarni AB, Pant HC (2002) Cyclin-dependent kinase 5 prevents neuronal apoptosis by negative regulation of c-Jun N-terminal kinase 3. EMBO J 21:324–333
pubmed: 11823425
pmcid: 125822
doi: 10.1093/emboj/21.3.324
Sharma P, Veeranna, Sharma M, Amin ND, Sihag RK, Grant P, Ahn N, Kulkarni AB et al (2002) Phosphorylation of MEK1 by cdk5/p35 down-regulates the mitogen-activated protein kinase pathway. J Biol Chem 277:528–534
pubmed: 11684694
doi: 10.1074/jbc.M109324200
Lapresa R, Agulla J, Sanchez-Moran I, Zamarreno R, Prieto E, Bolanos JP, Almeida A (2019) Amyloid-ss promotes neurotoxicity by Cdk5-induced p53 stabilization. Neuropharmacology 146:19–27
pubmed: 30452955
doi: 10.1016/j.neuropharm.2018.11.019
Shin BN, Kim DW, Kim IH, Park JH, Ahn JH, Kang IJ, Lee YL, Lee CH et al (2019) Down-regulation of cyclin-dependent kinase 5 attenuates p53-dependent apoptosis of hippocampal CA1 pyramidal neurons following transient cerebral ischemia. Sci Rep 9:13032
pubmed: 31506563
pmcid: 6737192
doi: 10.1038/s41598-019-49623-x
Chang KH, de Pablo Y, Lee HP, Lee HG, Smith MA, Shah K (2010) Cdk5 is a major regulator of p38 cascade: relevance to neurotoxicity in Alzheimer’s disease. J Neurochem 113:1221–1229
pubmed: 20345761
doi: 10.1111/j.1471-4159.2010.06687.x
NavaneethaKrishnan S, Law V, Lee J, Rosales JL, Lee KY (2022) Cdk5 regulates IP3R1-mediated Ca2+ dynamics and Ca2+-mediated cell proliferation. Cell Mol Life Sci 79
NavaneethaKrishnan S, Rosales JL, Lee KY (2020) mPTP opening caused by Cdk5 loss is due to increased mitochondrial Ca2+ uptake. Oncogene 39:2797–2806
pubmed: 32024968
pmcid: 7098883
doi: 10.1038/s41388-020-1188-5
Darios F, Muriel MP, Khondiker ME, Brice A, Ruberg M (2005) Neurotoxic calcium transfer from endoplasmic reticulum to mitochondria is regulated by cyclin-dependent kinase 5-dependent phosphorylation of tau. J Neurosci 25:4159–4168
pubmed: 15843619
pmcid: 6724963
doi: 10.1523/JNEUROSCI.0060-05.2005
Wang J, Liu SH, Fu YP, Wang JH, Lu YM (2003) Cdk5 activation induces hippocampal CA1 cell death by directly phosphorylating NMDA receptors. Nat Neurosci 6:1039–1047
pubmed: 14502288
doi: 10.1038/nn1119
Nikhil K, Shah K (2017) The Cdk5-Mcl-1 axis promotes mitochondrial dysfunction and neurodegeneration in a model of Alzheimer’s disease. J Cell Sci 130:3023–3039
pubmed: 28751497
pmcid: 5612176
Lee KY, Clark AW, Rosales JL, Chapman K, Fung T, Johnston RN (1999) Elevated neuronal Cdc2-like kinase activity in the Alzheimer disease brain. Neurosci Res 34:21–29
pubmed: 10413323
doi: 10.1016/S0168-0102(99)00026-7
Tseng HC, Zhou Y, Shen Y, Tsai LH (2002) A survey of Cdk5 activator p35 and p25 levels in Alzheimer’s disease brains. FEBS Lett 523:58–62
pubmed: 12123804
doi: 10.1016/S0014-5793(02)02934-4
Park J, Kim B, Chae U, Lee DG, Kam MK, Lee SR, Lee S, Lee HS et al (2017) Peroxiredoxin 5 decreases beta-amyloid-mediated cyclin-dependent kinase 5 activation through regulation of Ca2+-mediated calpain activation. Antioxid Redox Sign 27:715–726
doi: 10.1089/ars.2016.6810
Cruz JC, Tsai LH (2004) Cdk5 deregulation in the pathogenesis of Alzheimer’s disease. Trends Mol Med 10:452–458
pubmed: 15350898
doi: 10.1016/j.molmed.2004.07.001
Qu D, Rashidian J, Mount MP, Aleyasin H, Parsanejad M, Lira A, Haque E, Zhang Y et al (2007) Role of Cdk5-mediated phosphorylation of Prx2 in MPTP toxicity and Parkinson’s disease. Neuron 55:37–52
pubmed: 17610816
doi: 10.1016/j.neuron.2007.05.033
Smith PD, Crocker SJ, Jackson-Lewis V, Jordan-Sciutto KL, Hayley S, Mount MP, O’Hare MJ, Callaghan S et al (2003) Cyclin-dependent kinase 5 is a mediator of dopaminergic neuron loss in a mouse model of Parkinson’s disease. P Natl Acad Sci USA 100:13650–13655
doi: 10.1073/pnas.2232515100
Tang X, Wang X, Gong X, Tong M, Park D, Xia Z, Mao Z (2005) Cyclin-dependent kinase 5 mediates neurotoxin-induced degradation of the transcription factor myocyte enhancer factor 2. J Neurosci 25:4823–4834
pubmed: 15888658
pmcid: 6724765
doi: 10.1523/JNEUROSCI.1331-05.2005
Levine B, Kroemer G (2008) Autophagy in the pathogenesis of disease. Cell 132:27–42
pubmed: 18191218
pmcid: 2696814
doi: 10.1016/j.cell.2007.12.018
Liu F, Liang Z, Shi J, Yin D, El-Akkad E, Grundke-Iqbal I, Iqbal K, Gong CX (2006) PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners. FEBS Lett 580:6269–6274
pubmed: 17078951
pmcid: 1828604
doi: 10.1016/j.febslet.2006.10.033
Sengupta A, Novak M, Grundke-Iqbal I, Iqbal K (2006) Regulation of phosphorylation of tau by cyclin-dependent kinase 5 and glycogen synthase kinase-3 at substrate level. FEBS Lett 580:5925–5933
pubmed: 17045592
pmcid: 1679721
doi: 10.1016/j.febslet.2006.09.060
Chow HM, Guo D, Zhou JC, Zhang GY, Li HF, Herrup K, Zhang J (2014) CDK5 activator protein p25 preferentially binds and activates GSK3beta. Proc Natl Acad Sci U S A 111:E4887-4895
pubmed: 25331900
pmcid: 4234543
doi: 10.1073/pnas.1402627111
Engmann O, Giese KP (2009) Crosstalk between Cdk5 and GSK3beta: implications for Alzheimer’s Disease. Front Mol Neurosci 2:2
pubmed: 19521544
pmcid: 2694676
doi: 10.3389/neuro.02.002.2009
Hashiguchi M, Saito T, Hisanaga S, Hashiguchi T (2002) Truncation of CDK5 activator p35 induces intensive phosphorylation of Ser202/Thr205 of human tau. J Biol Chem 277:44525–44530
pubmed: 12226093
doi: 10.1074/jbc.M207426200
Huang Y, Huang W, Huang Y, Song P, Zhang M, Zhang HT, Pan S, Hu Y (2020) Cdk5 Inhibitory Peptide Prevents Loss of Neurons and Alleviates Behavioral Changes in p25 Transgenic Mice. J Alzheimers Dis 74:1231–1242
pubmed: 32144987
doi: 10.3233/JAD-191098
Zhou X, Huang J, Pan S, Xu M, He R, Ji Z, Hu Y (2016) Neurodegeneration-like pathological and behavioral changes in an AAV9-mediated p25 overexpression mouse model. J Alzheimers Dis 53:843–855
pubmed: 27258419
doi: 10.3233/JAD-160191
Florean C, Zampese E, Zanese M, Brunello L, Ichas F, De Giorgi F, Pizzo P (2008) High content analysis of gamma-secretase activity reveals variable dominance of presenilin mutations linked to familial Alzheimer’s disease. Biochim Biophys Acta 1783:1551–1560
pubmed: 18424271
doi: 10.1016/j.bbamcr.2008.03.012
Lee MS, Tsai LH (2003) Cdk5: one of the links between senile plaques and neurofibrillary tangles? J Alzheimers Dis 5:127–137
pubmed: 12719630
doi: 10.3233/JAD-2003-5207
Cruz JC, Kim D, Moy LY, Dobbin MM, Sun X, Bronson RT, Tsai LH (2006) p25/cyclin-dependent kinase 5 induces production and intraneuronal accumulation of amyloid beta in vivo. J Neurosci 26:10536–10541
pubmed: 17035538
pmcid: 6674706
doi: 10.1523/JNEUROSCI.3133-06.2006
Pant AC, Veeranna, Pant HC, Amin N (1997) Phosphorylation of human high molecular weight neurofilament protein (hNF-H) by neuronal cyclin-dependent kinase 5 (cdk5). Brain Res 765:259–266
pubmed: 9313898
doi: 10.1016/S0006-8993(97)00561-1
Veeranna, Shetty KT, Link WT, Jaffe H, Wang J, Pant HC (1995) Neuronal cyclin-dependent kinase-5 phosphorylation sites in neurofilament protein (NF-H) are dephosphorylated by protein phosphatase 2A. J Neurochem 64:2681–2690
pubmed: 7760048
doi: 10.1046/j.1471-4159.1995.64062681.x
Bk B, Skuntz S, Prochazkova M, Kesavapany S, Amin ND, Shukla V, Grant P, Kulkarni AB et al (2019) Overexpression of the Cdk5 inhibitory peptide in motor neurons rescue of amyotrophic lateral sclerosis phenotype in a mouse model. Hum Mol Genet 28:3175–3187
pubmed: 31189016
pmcid: 6859439
doi: 10.1093/hmg/ddz118
Shen K, Pender CL, Bar-Ziv R, Zhang H, Wickham K, Willey E, Durieux J, Ahmad Q et al (2022) Mitochondria as cellular and organismal signaling hubs. Annu Rev Cell Dev Biol 38:179–218
pubmed: 35804477
doi: 10.1146/annurev-cellbio-120420-015303
Youle RJ, van der Bliek AM (2012) Mitochondrial fission, fusion, and stress. Science 337:1062–1065
pubmed: 22936770
pmcid: 4762028
doi: 10.1126/science.1219855
Onyango IG, Dennis J, Khan SM (2016) Mitochondrial dysfunction in Alzheimer’s disease and the rationale for bioenergetics based therapies. Aging Dis 7:201–214
pubmed: 27114851
pmcid: 4809610
doi: 10.14336/AD.2015.1007
Rangaraju V, Lauterbach M, Schuman EM (2019) Spatially stable mitochondrial compartments fuel local translation during plasticity. Cell 176(73–84):e15
Todorova V, Blokland A (2017) Mitochondria and Synaptic Plasticity in the Mature and Aging Nervous System. Curr Neuropharmacol 15:166–173
pubmed: 27075203
pmcid: 5327446
doi: 10.2174/1570159X14666160414111821
Haelterman NA, Yoon WH, Sandoval H, Jaiswal M, Shulman JM, Bellen HJ (2014) A mitocentric view of Parkinson’s disease. Annu Rev Neurosci 37:137–159
pubmed: 24821430
pmcid: 4659514
doi: 10.1146/annurev-neuro-071013-014317
Hu H, Tan CC, Tan L, Yu JT (2017) A mitocentric view of Alzheimer’s disease. Mol Neurobiol 54:6046–6060
pubmed: 27696116
doi: 10.1007/s12035-016-0117-7
Chen C, Turnbull DM, Reeve AK (2019) Mitochondrial dysfunction in Parkinson's disease-cause or consequence? Biology (Basel) 8
Sprenger HG, Langer T (2019) The Good and the Bad of Mitochondrial Breakups. Trends Cell Biol 29:888–900
pubmed: 31495461
doi: 10.1016/j.tcb.2019.08.003
Swerdlow RH (2012) Mitochondria and cell bioenergetics: increasingly recognized components and a possible etiologic cause of Alzheimer’s disease. Antioxid Redox Sign 16:1434-U1163
doi: 10.1089/ars.2011.4149
Higgins CM, Jung C, Xu Z (2003) ALS-associated mutant SOD1G93A causes mitochondrial vacuolation by expansion of the intermembrane space and by involvement of SOD1 aggregation and peroxisomes. BMC Neurosci 4:16
pubmed: 12864925
pmcid: 169170
doi: 10.1186/1471-2202-4-16
Lin MT, Beal MF (2006) Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 443:787–795
pubmed: 17051205
doi: 10.1038/nature05292
Panov AV, Gutekunst CA, Leavitt BR, Hayden MR, Burke JR, Strittmatter WJ, Greenamyre JT (2002) Early mitochondrial calcium defects in Huntington’s disease are a direct effect of polyglutamines. Nat Neurosci 5:731–736
pubmed: 12089530
doi: 10.1038/nn884
Burte F, Carelli V, Chinnery PF, Yu-Wai-Man P (2015) Disturbed mitochondrial dynamics and neurodegenerative disorders. Nat Rev Neurol 11:11–24
pubmed: 25486875
doi: 10.1038/nrneurol.2014.228
Han XJ, Tomizawa K, Fujimura A, Ohmori I, Nishiki T, Matsushita M, Matsui H (2011) Regulation of mitochondrial dynamics and neurodegenerative diseases. Acta Med Okayama 65:1–10
pubmed: 21339790
Bera A, Lavanya G, Reshmi R, Dev K, Kumar R (2022) Mechanistic and therapeutic role of Drp1 in the pathogenesis of Alzheimer’s disease. Eur J Neurosci 56:5516–5531
pubmed: 35078269
doi: 10.1111/ejn.15611
Manczak M, Kandimalla R, Yin X, Reddy PH (2018) Hippocampal mutant APP and amyloid beta-induced cognitive decline, dendritic spine loss, defective autophagy, mitophagy and mitochondrial abnormalities in a mouse model of Alzheimer’s disease. Hum Mol Genet 27:1332–1342
pubmed: 29408999
pmcid: 6455948
doi: 10.1093/hmg/ddy042
Dorn GW 2nd (2019) Evolving Concepts of Mitochondrial Dynamics. Annu Rev Physiol 81:1–17
pubmed: 30256725
doi: 10.1146/annurev-physiol-020518-114358
Chan DC (2012) Fusion and fission: interlinked processes critical for mitochondrial health. Annu Rev Genet 46:265–287
pubmed: 22934639
doi: 10.1146/annurev-genet-110410-132529
Palikaras K, Lionaki E, Tavernarakis N (2018) Mechanisms of mitophagy in cellular homeostasis, physiology and pathology. Nat Cell Biol 20:1013–1022
pubmed: 30154567
doi: 10.1038/s41556-018-0176-2
Meuer K, Suppanz IE, Lingor P, Planchamp V, Goricke B, Fichtner L, Braus GH, Dietz GPH et al (2007) Cyclin-dependent kinase 5 is an upstream regulator of mitochondrial fission during neuronal apoptosis. Cell Death Differ 14:651–661
pubmed: 17218957
doi: 10.1038/sj.cdd.4402087
Kraus F, Ryan MT (2017) The constriction and scission machineries involved in mitochondrial fission. J Cell Sci 130:2953–2960
pubmed: 28842472
Smirnova E, Griparic L, Shurland DL, van der Bliek AM (2001) Dynamin-related protein Drp1 is required for mitochondrial division in mammalian cells. Mol Biol Cell 12:2245–2256
pubmed: 11514614
pmcid: 58592
doi: 10.1091/mbc.12.8.2245
Chang CR, Blackstone C (2010) Dynamic regulation of mitochondrial fission through modification of the dynamin-related protein Drp1. Ann N Y Acad Sci 1201:34–39
pubmed: 20649536
pmcid: 5585781
doi: 10.1111/j.1749-6632.2010.05629.x
Mishra P, Chan DC (2016) Metabolic regulation of mitochondrial dynamics. J Cell Biol 212:379–387
pubmed: 26858267
pmcid: 4754720
doi: 10.1083/jcb.201511036
Cho B, Cho HM, Kim HJ, Jeong J, Park SK, Hwang EM, Park JY et al. (2014) CDK5-dependent inhibitory phosphorylation of Drp1 during neuronal maturation. Exp Mol Med 46
Guo MY, Shang L, Hu YY, Jiang LP, Wan YY, Zhou QQ, Zhang K, Liao HF et al (2018) The role of Cdk5-mediated Drp1 phosphorylation in A(1–42) induced mitochondrial fission and neuronal apoptosis. J Cell Biochem 119:4815–4825
pubmed: 29345339
doi: 10.1002/jcb.26680
Baek SH, Park SJ, Jeong JI, Kim SH, Han J, Kyung JW, Baik SH, Choi Y, Choi BY, Park JS et al (2017) Inhibition of Drp1 Ameliorates Synaptic Depression, Abeta Deposition, and Cognitive Impairment in an Alzheimer’s Disease Model. J Neurosci 37:5099–5110
pubmed: 28432138
pmcid: 6596467
doi: 10.1523/JNEUROSCI.2385-16.2017
Xu D, Yang P, Yang ZJ, Li QG, Ouyang YT, Yu T, Shangguan JH, Wan YY, et al (2021) Blockage of Drp1 phosphorylation at Ser579 protects neurons against A beta(1–42)-induced degeneration. Mol Med Rep 24
Park J, Seo J, Won J, Yeo HG, Ahn YJ, Kim K, Jin YB, Koo BS, Lim KS, Jeong KJ et al (2019) Abnormal mitochondria in a non-human primate model of MPTP-induced Parkinson’s disease: Drp1 and CDK5/p25 signaling. Exp Neurobiol 28:414–424
pubmed: 31308800
pmcid: 6614070
doi: 10.5607/en.2019.28.3.414
Yang SH, Huang CY, Hsieh CY, Chuang JI (2020) CDK4 and CDK5 inhibition have comparable mild hypothermia effects in preventing Drp1-dependent mitochondrial fission and neuron death induced by MPP+. Mol Neurobiol 57:4090–4105
pubmed: 32666227
doi: 10.1007/s12035-020-02014-0
Cherubini M, Puigdellivol M, Alberch J, Gines S (2015) Cdk5-mediated mitochondrial fission: A key player in dopaminergic toxicity in Huntington’s disease. Bba-Mol Basis Dis 1852:2145–2160
doi: 10.1016/j.bbadis.2015.06.025
Park J, Choi H, Min JS, Kim B, Lee SR, Yun JW, Choi MS, Chang KT et al (2015) Loss of mitofusin 2 links beta-amyloid-mediated mitochondrial fragmentation and Cdk5-induced oxidative stress in neuron cells. J Neurochem 132:687–702
pubmed: 25359615
doi: 10.1111/jnc.12984
Dionisio PA, Amaral JD, Rodrigues CMP (2021) Oxidative stress and regulated cell death in Parkinson’s disease. Ageing Res Rev 67:101263
pubmed: 33540042
doi: 10.1016/j.arr.2021.101263
Niedzielska E, Smaga I, Gawlik M, Moniczewski A, Stankowicz P, Pera J, Filip M (2016) Oxidative stress in neurodegenerative diseases. Mol Neurobiol 53:4094–4125
pubmed: 26198567
doi: 10.1007/s12035-015-9337-5
Wang X, Wang W, Li L, Perry G, Lee HG, Zhu X (2014) Oxidative stress and mitochondrial dysfunction in Alzheimer’s disease. Biochim Biophys Acta 1842:1240–1247
pubmed: 24189435
doi: 10.1016/j.bbadis.2013.10.015
Nunnari J, Suomalainen A (2012) Mitochondria: in sickness and in health. Cell 148:1145–1159
pubmed: 22424226
pmcid: 5381524
doi: 10.1016/j.cell.2012.02.035
Ott M, Gogvadze V, Orrenius S, Zhivotovsky B (2007) Mitochondria, oxidative stress and cell death. Apoptosis 12:913–922
pubmed: 17453160
doi: 10.1007/s10495-007-0756-2
Sun KH, de Pablo Y, Vincent F, Shah K (2008) Deregulated Cdk5 promotes oxidative stress and mitochondrial dysfunction. J Neurochem 107:265–278
pubmed: 18691386
doi: 10.1111/j.1471-4159.2008.05616.x
Xie H, Hou S, Jiang J, Sekutowicz M, Kelly J, Bacskai BJ (2013) Rapid cell death is preceded by amyloid plaque-mediated oxidative stress. Proc Natl Acad Sci U S A 110:7904–7909
pubmed: 23610434
pmcid: 3651444
doi: 10.1073/pnas.1217938110
Schwartz M, Ziv Y (2008) Immunity to self and self-maintenance: a unified theory of brain pathologies. Trends Immunol 29:211–219
pubmed: 18328784
doi: 10.1016/j.it.2008.01.003
Wyss-Coray T, Mucke L (2002) Inflammation in neurodegenerative disease–a double-edged sword. Neuron 35:419–432
pubmed: 12165466
doi: 10.1016/S0896-6273(02)00794-8
Liu B, Hong JS (2003) Role of microglia in inflammation-mediated neurodegenerative diseases: mechanisms and strategies for therapeutic intervention. J Pharmacol Exp Ther 304:1–7
pubmed: 12490568
doi: 10.1124/jpet.102.035048
Kang SW, Rhee SG, Chang TS, Jeong W, Choi MH (2005) 2-Cys peroxiredoxin function in intracellular signal transduction: therapeutic implications. Trends Mol Med 11:571–578
pubmed: 16290020
pmcid: 7185838
doi: 10.1016/j.molmed.2005.10.006
Sandoval R, Lazcano P, Ferrari F, Pinto-Pardo N, Gonzalez-Billault C, Utreras E (2018) TNF-alpha Increases production of reactive oxygen species through Cdk5 activation in nociceptive neurons. Front Physiol 9
Liddelow SA, Guttenplan KA, Clarke LE, Bennett FC, Bohlen CJ, Schirmer L, Bennett ML, Munch AE et al (2017) Neurotoxic reactive astrocytes are induced by activated microglia. Nature 541:481–487
pubmed: 28099414
pmcid: 5404890
doi: 10.1038/nature21029
Takahashi S, Ohshima T, Hirasawa M, Pareek TK, Bugge TH, Morozov A, Fujieda K, Brady RO et al (2010) Conditional deletion of neuronal cyclin-dependent kinase 5 in developing forebrain results in microglial activation and neurodegeneration. Am J Pathol 176:320–329
pubmed: 19948833
pmcid: 2797893
doi: 10.2353/ajpath.2010.081158
Crews L, Patrick C, Adame A, Rockenstein E, Masliah E (2011) Modulation of aberrant CDK5 signaling rescues impaired neurogenesis in models of Alzheimer’s disease. Cell Death Dis 2:e120
pubmed: 21368891
pmcid: 3101702
doi: 10.1038/cddis.2011.2
Wilkaniec A, Czapski GA, Adamczyk A (2016) Cdk5 at crossroads of protein oligomerization in neurodegenerative diseases: facts and hypotheses. J Neurochem 136:222–233
pubmed: 26376455
doi: 10.1111/jnc.13365
Sundaram JR, Chan ES, Poore CP, Pareek TK, Cheong WF, Shui G, Tang N, Low CM et al (2012) Cdk5/p25-induced cytosolic PLA2-mediated lysophosphatidylcholine production regulates neuroinflammation and triggers neurodegeneration. J Neurosci 32:1020–1034
pubmed: 22262900
pmcid: 6621136
doi: 10.1523/JNEUROSCI.5177-11.2012
Sundaram JR, Poore CP, Sulaimee NH, Pareek T, Asad AB, Rajkumar R, Cheong WF, Wenk MR et al (2013) Specific inhibition of p25/Cdk5 activity by the Cdk5 inhibitory peptide reduces neurodegeneration in vivo. J Neurosci 33:334–343
pubmed: 23283346
pmcid: 6618624
doi: 10.1523/JNEUROSCI.3593-12.2013
Paul S, Fatihi S, Sharma S, Kutum R, Fields R, Pant HC, Thukral L, Bk B (2022) Cyclin-dependent kinase 5 regulates cPLA2 activity and neuroinflammation in Parkinson's disease. eNeuro 9
Avraham E, Rott R, Liani E, Szargel R, Engelender S (2007) Phosphorylation of parkin by the cyclin-dependent kinase 5 at the linker region modulates its ubiquitin-ligase activity and aggregation. J Biol Chem 282:12842–12850
pubmed: 17327227
doi: 10.1074/jbc.M608243200
Rubio de la Torre E, Luzon-Toro B, Forte-Lago I, Minguez-Castellanos A, Ferrer I, Hilfiker S (2009) Combined kinase inhibition modulates parkin inactivation. Hum Mol Genet 18:809–823
pubmed: 19050041
Nandi N, Tyra LK, Stenesen D, Kramer H (2017) Stress-induced Cdk5 activity enhances cytoprotective basal autophagy in Drosophila melanogaster by phosphorylating acinus at serine(437). eLife 6
Shukla AK, Spurrier J, Kuzina I, Giniger E (2019) Hyperactive innate immunity causes degeneration of dopamine neurons upon altering activity of Cdk5. Cell Rep 26:131-+
pubmed: 30605670
pmcid: 6442473
doi: 10.1016/j.celrep.2018.12.025
Lee S, Sato Y, Nixon RA (2011) Lysosomal proteolysis inhibition selectively disrupts axonal transport of degradative organelles and causes an Alzheimer’s-like axonal dystrophy. J Neurosci 31:7817–7830
pubmed: 21613495
pmcid: 3351137
doi: 10.1523/JNEUROSCI.6412-10.2011
Nixon RA (2013) The role of autophagy in neurodegenerative disease. Nat Med 19:983–997
pubmed: 23921753
doi: 10.1038/nm.3232
Park KH, Lu G, Fan J, Raymond LA, Leavitt BR (2012) Decreasing levels of the cdk5 Activators, p25 and p35, reduces excitotoxicity in striatal neurons. J Huntingtons Dis 1:89–96
pubmed: 24353748
doi: 10.3233/JHD-2012-129000
Li BS, Sun MK, Zhang L, Takahashi S, Ma W, Vinade L, Kulkarni AB, Brady RO et al (2001) Regulation of NMDA receptors by cyclin-dependent kinase-5. Proc Natl Acad Sci U S A 98:12742–12747
pubmed: 11675505
pmcid: 60124
doi: 10.1073/pnas.211428098
Hyun HW, Min SJ, Kim JE (2017) CDK5 inhibitors prevent astroglial apoptosis and reactive astrogliosis by regulating PKA and DRP1 phosphorylations in the rat hippocampus. Neurosci Res 119:24–37
pubmed: 28153522
doi: 10.1016/j.neures.2017.01.006
Meijer L, Borgne A, Mulner O, Chong JP, Blow JJ, Inagaki N, Inagaki M, Delcros JG et al (1997) Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur J Biochem 243:527–536
pubmed: 9030781
doi: 10.1111/j.1432-1033.1997.t01-2-00527.x
Quan Q, Qian Y, Li X, Li M (2019) CDK5 participates in amyloid-beta production by regulating PPARgamma phosphorylation in primary rat hippocampal neurons. J Alzheimers Dis 71:443–460
pubmed: 31403945
doi: 10.3233/JAD-190026
Liu F, Ma XH, Ule J, Bibb JA, Nishi A, DeMaggio AJ, Yan Z, Nairn AC et al (2001) Regulation of cyclin-dependent kinase 5 and casein kinase 1 by metabotropic glutamate receptors. Proc Natl Acad Sci U S A 98:11062–11068
pubmed: 11572969
pmcid: 58683
doi: 10.1073/pnas.191353898
Song Y, Kesuma D, Wang J, Deng Y, Duan J, Wang JH, Qi RZ (2004) Specific inhibition of cyclin-dependent kinases and cell proliferation by harmine. Biochem Biophys Res Commun 317:128–132
pubmed: 15047157
doi: 10.1016/j.bbrc.2004.03.019
Bukanov NO, Smith LA, Klinger KW, Ledbetter SR, Ibraghimov-Beskrovnaya O (2006) Long-lasting arrest of murine polycystic kidney disease with CDK inhibitor roscovitine. Nature 444:949–952
pubmed: 17122773
doi: 10.1038/nature05348
Camins A, Verdaguer E, Folch J, Canudas AM, Pallàs M (2006) The role of CDK5/P25 formation/inhibition in neurodegeneration. Drug News Perspect 19:453–460
pubmed: 17160145
doi: 10.1358/dnp.2006.19.8.1043961
Cicenas J, Kalyan K, Sorokinas A, Stankunas E, Levy J, Meskinyte I, Stankevicius V, Kaupinis A et al (2015) Roscovitine in cancer and other diseases. Annal Transl Med 3:135
Veselý J, Havlicek L, Strnad M, Blow JJ, Donella-Deana A, Pinna L, Letham DS, Kato J et al (1994) Inhibition of cyclin-dependent kinases by purine analogues. Eur J Biochem 224:771–786
pubmed: 7925396
doi: 10.1111/j.1432-1033.1994.00771.x
Squires MS, Feltell RE, Wallis NG, Lewis EJ, Smith DM, Cross DM, Lyons JF, Thompson NT (2009) Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines. Mol Cancer Ther 8:324–332
pubmed: 19174555
doi: 10.1158/1535-7163.MCT-08-0890
Zhang B, Tan VB, Lim KM, Tay TE, Zhuang S (2007) Study of the inhibition of cyclin-dependent kinases with roscovitine and indirubin-3’-oxime from molecular dynamics simulations. J Mol Model 13:79–89
pubmed: 16770643
doi: 10.1007/s00894-006-0127-x
Hallek M (2013) Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment. Am J Hematol 88:803–816
pubmed: 23720127
doi: 10.1002/ajh.23491
Parry D, Guzi T, Shanahan F, Davis N, Prabhavalkar D, Wiswell D, Seghezzi W, Paruch K et al (2010) Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor. Mol Cancer Ther 9:2344–2353
pubmed: 20663931
doi: 10.1158/1535-7163.MCT-10-0324
Mariaule G, Belmont P (2014) Cyclin-dependent kinase inhibitors as marketed anticancer drugs: where are we now? A short survey. Molecules (Basel, Switzerland) 19:14366–14382
pubmed: 25215591
doi: 10.3390/molecules190914366
Zheng YL, Li C, Hu YF, Cao L, Wang H, Li B, Lu XH, Bao L et al (2013) Cdk5 inhibitory peptide (CIP) inhibits Cdk5/p25 activity induced by high glucose in pancreatic beta cells and recovers insulin secretion from p25 damage. PLoS One 8:e63332
pubmed: 24039692
pmcid: 3764143
doi: 10.1371/journal.pone.0063332
Fang WH, Kumar S, McDowell G, Smith D, Krupinski J, Olah P, Al-Baradie RS, Al-Rukban MO et al (2016) Mesenchymal stem cells loaded with p5, derived from CDK5 activator p35, inhibit calcium-induced CDK5 activation in endothelial cells. Stem Cells Int 2016:2165462
pubmed: 27651795
pmcid: 5019892
doi: 10.1155/2016/2165462
Zhang B, Corbel C, Guéritte F, Couturier C, Bach S, Tan VB (2011) An in silico approach for the discovery of CDK5/p25 interaction inhibitors. Biotechnol J 6:871–881
pubmed: 21681969
doi: 10.1002/biot.201100139
Kitazawa M, Oddo S, Yamasaki TR, Green KN, LaFerla FM (2005) Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer’s disease. J Neurosci 25:8843–8853
pubmed: 16192374
pmcid: 6725603
doi: 10.1523/JNEUROSCI.2868-05.2005
Chen Y, Hou Y, Ge R, Han J, Xu J, Chen J, Wang H (2018) Protective effect of roscovitine against rotenone-induced parkinsonism. Restor Neurol Neurosci 36:629–638
pubmed: 30056439
Chergui K, Svenningsson P, Greengard P (2004) Cyclin-dependent kinase 5 regulates dopaminergic and glutamatergic transmission in the striatum. Proc Natl Acad Sci U S A 101:2191–2196
pubmed: 14769920
pmcid: 357074
doi: 10.1073/pnas.0308652100
Pao PC, Seo J, Lee A, Kritskiy O, Patnaik D, Penney J, Raju RM, Geigenmuller U et al (2023) A Cdk5-derived peptide inhibits Cdk5/p25 activity and improves neurodegenerative phenotypes. Proc Natl Acad Sci U S A 120:e2217864120
pubmed: 37043533
pmcid: 10120002
doi: 10.1073/pnas.2217864120
Zhang QS, Xie HF, Ji Z, He RN, Xu MJ, He Y, Huang JN, Pan SY et al (2016) Cdk5/p25 specific inhibitory peptide TFP5 rescues the loss of dopaminergic neurons in a sub-acute MPTP induced PD mouse model. Neurosci Lett 632:1–7
pubmed: 27542341
doi: 10.1016/j.neulet.2016.08.023
Lin L, Liu XD, Cheng XJ, Li YJ, Gearing M, Levey A, Huang XL, Li Y, et al. (2023) MicroRNA-650 regulates the pathogenesis of Alzheimer's disease through targeting cyclin-dependent kinase 5. Mol Neurobiol